Why AP called Arizona for Trump
Trump wins Arizona, sweeping all seven battleground states, Edison Research says
China, Indonesia enhance ties with key deals on lithium, green energy, tourism
Soldier with Yemen's exiled government opens fire, killing 2 Saudi troops and wounding another
US to speed up interceptor missiles delivery to Ukraine, WSJ reports
US ordered TSMC to halt shipments to China of chips used in AI applications, source says
Justin Allgaier wins 1st NASCAR Xfinity title, capping comeback by passing Hill and Custer late
Evan Mobley scores 23 points and Cavaliers rally past Nets 105-100 to remain perfect at 11-0
Judith Jamison, transcendent dancer and artistic director of Alvin Ailey company, dies at 81
(Reuters) - Moderna shares fell 6% on Friday after a longer-term analysis of a trial indicated a quicker fall in the efficacy of its experimental respiratory syncytial virus (RSV) vaccine.
At least two analysts pointed to the data, posted ahead of a conference on RSV next week, that showed a vaccine efficacy of about 63% after 8.6 months, from 84% at 3.3 months.
Pfizer's vaccine efficacy went from 67% to 49% in 17 months, while GSK's fell to 77% at 14 months from 83%, TD Cowen analyst Tyler Van Buren said.
The data suggests Moderna's RSV vaccine efficacy is "declining quicker than the GSK and Pfizer vaccines," he said.
Moderna's shares were at $88 in morning trading, and were on track for their biggest one-day fall since November.
(Reporting by Manas Mishra in Bengaluru; Editing by Sriraj Kalluvila)
